157 related articles for article (PubMed ID: 37760780)
1. A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice.
Kakimoto T; Ogasawara A; Ishikawa K; Kurita T; Yoshida K; Harada S; Nonaka T; Inoue Y; Uchida K; Tateoka T; Ohta T; Kumagai S; Sasaki T; Aihara H
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760780
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy.
Bouwman LF; den Hamer B; van den Heuvel A; Franken M; Jackson M; Dwyer CA; Tapscott SJ; Rigo F; van der Maarel SM; de Greef JC
Mol Ther Nucleic Acids; 2021 Dec; 26():813-827. PubMed ID: 34729250
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
4. Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy.
Lu-Nguyen N; Malerba A; Antoni Pineda M; Dickson G; Popplewell L
Hum Gene Ther; 2022 Sep; 33(17-18):923-935. PubMed ID: 35078334
[TBL] [Abstract][Full Text] [Related]
5. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
[TBL] [Abstract][Full Text] [Related]
6. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit
Lu-Nguyen N; Dickson G; Malerba A; Popplewell L
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884928
[TBL] [Abstract][Full Text] [Related]
8. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of
Lim KRQ; Maruyama R; Echigoya Y; Nguyen Q; Zhang A; Khawaja H; Sen Chandra S; Jones T; Jones P; Chen YW; Yokota T
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16509-16515. PubMed ID: 32601200
[TBL] [Abstract][Full Text] [Related]
10. Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies.
Greco A; Straasheijm KR; Mul K; van den Heuvel A; van der Maarel SM; Joosten LAB; van Engelen BGM; Pruijn GJM
J Neuromuscul Dis; 2021; 8(5):801-814. PubMed ID: 34024774
[TBL] [Abstract][Full Text] [Related]
11. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells.
Lim KRQ; Yokota T
Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
13. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
14. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
15. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
16. Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.
Moyle LA; Blanc E; Jaka O; Prueller J; Banerji CR; Tedesco FS; Harridge SD; Knight RD; Zammit PS
Elife; 2016 Nov; 5():. PubMed ID: 27841748
[TBL] [Abstract][Full Text] [Related]
17. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
18. Molecular and Phenotypic Changes in FLExDUX4 Mice.
Murphy K; Zhang A; Bittel AJ; Chen YW
J Pers Med; 2023 Jun; 13(7):. PubMed ID: 37511653
[TBL] [Abstract][Full Text] [Related]
19. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
20. A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy.
Jones T; Jones PL
PLoS One; 2018; 13(2):e0192657. PubMed ID: 29415061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
